DIRS.INFO The most relevant business & tech news

☆ 'Europe is lagging behind' on innovation, says Merck KGaA CEO
▼ + stars: | 2024-01-18 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email'Europe is lagging behind' on innovation, says Merck KGaA CEOBelén Garijo, CEO of Merck KGaA, discusses European regulation, growth and innovation with CNBC at Davos.

Persons: Merck, Belén Garijo, Merck KGaA Organizations: Merck, CNBC Locations: Davos

☆ Morning Bid: Range-bound markets awaits Powell - again
▼ + stars: | 2023-11-09 | by ( ) www.reuters.com time to read: +3 min

Federal Reserve Board Chair Jerome Powell answers a question during a press conference following a two-day meeting of the Federal Open Market Committee on interest rate policy in Washington, U.S., November 1, 2023. At a separate event on Wednesday, European Central Bank chief economist Philip Lane said his bank needs to see further progress in dampening inflationary pressure, and companies along with governments need to chip in to prevent more policy tightening. "A decrease in the policy rate is not something that is likely to happen in the short term," he said. The approval paves the way for a powerful rival to blockbuster drug Wegovy in addressing record obesity rates. Ping An subsequently said in a statement to Reuters it had "not been asked by (the) Government to take over Country Garden".

Persons: Jerome Powell, Kevin Lamarque, Ankur Banerjee, Powell, Philip Lane, Patrick Harker, Huw Pill, Eli Lilly's, Ping, Merck KGaA, BOE, Christopher Cushing Organizations: Federal, Committee, REUTERS, Ankur, U.S, European Central Bank, . Federal Reserve Bank of Philadelphia, Bank of England, Investors, Novo Nordisk, Reuters, Ping An Insurance, Government, HK, AstraZeneca, Merck, Deutsche Telekom Speakers, Thomson Locations: Washington , U.S, Asia, Guangdong, Ping, Singapore

☆ Pro Take: Making Medicines Greener
▼ + stars: | 2023-10-19 | by ( Cecilia Butini | ) www.wsj.com time to read: +6 min

Photo: mohamed hossam/ShutterstockMaking and supplying medicines generates roughly a third of the global healthcare industry’s greenhouse-gas emissions. Photo: Carlos Jasso/Bloomberg NewsBritish drugmaker GSK , for instance, plans to run on 100% renewable electricity by 2025 and to reach net-zero emissions across its value chain by 2045. GSK partnered with AstraZeneca , Merck KGaA, Novo Nordisk , Roche Holding , Samsung Biologics and Sanofi to form the SMI Health Systems Task Force in 2021. Last year, the partnership decided to strengthen their collaboration by focusing on cutting emissions in the near term and transitioning faster toward net-zero health systems. Novartis aims to achieve net-zero emissions across its value chain by 2040.

Persons: mohamed hossam, Carlos Jasso, “ We’ve, ”, Mike Peirce, Aurelio Arias, Arias, Claire Lund, Sanofi, Annabelle Harreguy, IQVIA’s Arias, “ It’s, ” Arias, Cecilia Butini Organizations: Pharmaceutical, Pharma, GSK, Bloomberg News British, Climate Group, Climate, Business, Sustainable Markets, Health Systems, Force, AstraZeneca, Merck KGaA, Novo Nordisk, Roche Holding, Samsung Biologics, Sanofi, SMI, Systems, Novartis, World Health Organization, cecilia.butini@wsj.com Locations: GSK’s, China, India, Novo

☆ Merck KGaA raises prospect of return to sales growth next year
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +3 min

A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. The market for semiconductor materials sold by the company's Electronics division, should "recover incrementally in 2024", Merck added. The company reaffirmed that sales would be broadly flat this year, at between 20.5 billion euros ($21.6 billion) and 21.9 billion euros, compared with 22.2 billion last year. The outlook for adjusted core earnings of 5.8 billion to 6.4 billion euros this year, down from 6.85 billion in 2022, was also confirmed. Higher interest rates have dampened investor appetite for risky biotech drug ventures, compounding a decline in coronavirus-related activities.

Persons: Ralph Orlowski, Belen Garijo, Morgan, Merck, JP Morgan, Garijo, Ludwig Burger, Rachel More, Elaine Hardcastle Organizations: Merck, REUTERS, company's Electronics, Lonza, Reuters, Thomson Locations: Darmstadt, Germany, FRANKFURT, coronavirus, Swiss

☆ Merck KGaA says MS drug has blockbuster potential; key data expected in December
▼ + stars: | 2023-10-19 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

Merck, seen as leading the race to win approval for a more targeted type of MS drug, said in April that U.S. regulators had paused enrolment of new patients into a trial testing the drug, evobrutinib, knocking the German drugmaker's share price. "The readout of our Phase 3 study is going to happen in December," she added of the pivotal study in the clinical trials process. Novartis (NOVN.S), also in the race, said in April that no signs of liver damage had been seen in trials testing its anti-inflammatory drug candidate remibrutinib so far. Roche (ROG.S) said in May that its BTK inhibitor against MS, reduced brain lesions associated with the disease in a mid-stage trial and that no new safety concerns had emerged. Reporting by Ludwig Burger Editing by Bill BerkrotOur Standards: The Thomson Reuters Trust Principles.

Persons: Germany's Merck, Belen Garijo, ROG.S, Ludwig Burger, Bill Berkrot Organizations: Germany's, Merck, U.S . Food, Drug Administration, Reuters, Rivals, Sanofi, Novartis, Thomson Locations: FRANKFURT, U.S, Darmstadt

The logo of Swiss contract drug maker Lonza is seen at its headquarters in Basel, Switzerland October 1, 2020. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, dropped 5.3% shortly after the 0700 GMT market open, trading near an eight-month low. A former Roche executive who joined Lonza in 2020, Ruffieux oversaw the company's role in producing COVID-19 vaccines for Moderna (MRNA.O) during the pandemic. "Today’s announcement increases our conviction that the new mid-term targets will not include an acceleration in growth," they said. Lonza did not provide a reason for Ruffieux's departure.

Persons: Arnd, Pierre, Alain Ruffieux, Lonza, Albert Baehny, Ruffieux, Morgan, Spokespeople, Merck KGaA, Noele, Ludwig Burger, Rachel More, David Goodman, Emelia Organizations: REUTERS, Monday, Ruffieux, Roche, Lonza, Moderna, Merck, Noele Illien, Thomson Locations: Basel, Switzerland, Swiss, Lonza, Zurich, Frankfurt

A general view of the drug product manufacturing laboratory in biologics and sterile injectables, Catalent, in Brussels, Belgium June 27, 2023. Catalent named three pharma industry executives and a senior Elliott executive to its board and said John Greisch, who has served on the board since 2018, will become executive chairman. Elliott, whose stake in Catalent became public last month, has been engaging with the company behind the scenes for months. Two of the directors were picked by Elliott, while two were mutually agreed by Elliott and Catalent. Catalent is also forming a new strategic and operational review committee which Greisch will chair.

Persons: Yves Herman, Elliott, Catalent, Alessandro Maselli, John Greisch, Max, William Blair, Maselli, Steven Barg, Goldman Sachs, Frank D'Amelio, Stephanie Okey, Michelle Ryan, Greisch, Merck KGaA, Svea Herbst, Bayliss, Maggie Fick, Sriparna Roy, Shinjini Ganguli, Catherine Evans, Mike Harrison Organizations: REUTERS, Catalent Inc, Elliott Investment Management, Reuters, Novo, pharma, U.S . Food, Drug Administration, Pfizer, Johnson, Catalent, Svea, Thomson Locations: Brussels, Belgium, ., Danish, Novo, United States, Catalent, GLP, Boston, London, Bengaluru

☆ Germany's Merck flags steeper drop in earnings
▼ + stars: | 2023-08-03 | by ( Ludwig Burger | ) www.reuters.com time to read: +2 min

A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. Earnings before interest, taxes, depreciation and amortisation (EBITDA), before one-offs, would fall between 3% and 9%, when adjusted for currency swings, the diversified company said. The foreign exchange effects would be an additional drag of between 3% and 6%, it added. It had previously forecast 2023 adjusted EBITDA to slip between 0% and 5%, with an additional negative foreign exchange effect of 2% to 5%. Merck also reported second-quarter adjusted EBITDA declined 12.8% to 1.55 billion euros ($1.69 billion), slightly above the average estimate of 1.5 billion euros in an analyst poll on the company's website.

Persons: Ralph Orlowski, Merck, drugmakers, Ludwig Burger, Maria Sheahan, Miranda Murray, Kim Coghill Organizations: Merck, REUTERS, Science, Thomson Locations: Darmstadt, Germany, COVID

☆ Exclusive: MoonLake Immunotherapeutics explores sale-sources
▼ + stars: | 2023-07-14 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

July 14 (Reuters) - MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter. Immunology-focused companies have been coveted acquisition targets, as highlighted by recent deals such as Merck & Co's (MRK.N) $10.8 billion acquisition of Prometheus BioSciences Inc and Eli Lilly's (LLY.N) $2.4 billion purchase of Dice Therapeutics (DICE.O). MoonLake is testing Sonelokimab for the treatment of other inflammatory conditions, including psoriatic arthritis and psoriasis. If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG (NOVN.S) and AbbVie Inc (ABBV.N). In 2022, MoonLake went public through a merger with a special purpose acquisition company, which helped it raise more than $200 million in cash.

Persons: drugmakers, Eli Lilly's, MoonLake, hidradenitis suppurativa, hidradenitis, Merck KGaA, David Carnevali, Josie Kao Organizations: Nasdaq, Merck, Co's, Prometheus BioSciences, Dice Therapeutics, Novartis AG, AbbVie Inc, Citigroup, Thomson Locations: Zug, Switzerland, New York

FRANKFURT, June 6 (Reuters) - The CEO of German technology group Merck KGaA (MRCG.DE) said that unravelling trade ties with China would come at great economic costs and that she was banking on dialogue to ease tensions between Beijing and Western powers. Belen Garijo, the Spanish CEO of the German maker of drugs, lab equipment and semiconductor chemicals, said late on Monday that dependencies between the powers were huge, speaking at a journalist club event in Frankfurt. But the two sides on Tuesday described meetings after the incident between senior U.S. and Chinese officials as constructive. For months, U.S. and German lawmakers have called for a reduction in trade to cut dependency on China. CEO Garijo said the company would look closely into "different scenarios on the basis of the potential escalation of the conflict", but such an escalation was not likely.

Persons: Belen Garijo, Garijo, Robert Habeck, Chancellor Olaf Scholz's, Ludwig Burger, Patricia Weiss, David Evans Organizations: Merck, U.S, Thomson Locations: FRANKFURT, China, Beijing, Spanish, Frankfurt, Chinese, U.S, Taiwan, Berlin

☆ Helene von Roeder to become new CFO of Germany's Merck
▼ + stars: | 2023-05-08 | by ( ) www.reuters.com time to read: 1 min

[1/2] People sit next to a Merck logo at SEMICON Taiwan in Taipei, Taiwan, September 14, 2022. REUTERS/Ann WangMay 8 (Reuters) - Germany's Merck KGaA (MRCG.DE) has appointed Helene von Roeder as the new chief financial officer and member of the Executive Board after Marcus Kuhnert has decided to step down, the drugmaker announced on Monday. The changes would become effective from July 1, the company added. German real estate company Vonovia (VNAn.DE) announced this month that von Roeder would be leaving its management board at her own request as of July 1. (This story has been refiled to make it clear that the company is Germany's Merck)Reporting by Anastasiia Kozlova and Amir Orusov Editing by Miranda MurrayOur Standards: The Thomson Reuters Trust Principles.

☆ Germany may restrict export of chip chemicals to China - Bloomberg
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +3 min

April 27 (Reuters) - Germany may limit the export of chemicals to China that are used to manufacture semiconductors as part of the government's efforts to reduce its economic exposure to the Asian economic superpower, Bloomberg news reported on Thursday. It would be the latest in steps under consideration by Germany as it reassesses ties with China. Merck KGaA (MRCG.DE) and BASF (BASFn.DE), two German chemicals majors who could be affected by the export curbs if implemented, declined comment. German Economy Minister Robert Habeck had in March suggested that Berlin could impose export restrictions to China to prevent Germany from losing its technological edge. "Export controls with regard to technology must be constantly checked, constantly expanded and constantly updated," a government spokesperson added at the time.

☆ EU considers ban on 'forever chemicals', urges search for alternatives
▼ + stars: | 2023-02-07 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

"A ban on PFAS would reduce quantities of PFAS in the environment over the long term. Once the ban is in force, companies will be given between 18 months and 12 years to introduce alternatives to the more than 10,000 PFAS affected, depending on the availability of alternatives, according to the draft proposal. The FPP4EU group of 14 companies that make and use PFAS has said that finding alternatives is a long and difficult process. Within the European Chemicals Agency (ECHA), two scientific committees for Risk Assessment and for Socio-Economic Analysis will now review whether the proposal to ban PFAS conforms with wider EU regulation of chemicals known as REACH, followed by a scientific evaluation and consultation with the industry. In August, the United States government said it will propose designating certain forever chemicals as hazardous substances under the U.S. Superfund programme.

☆ Drug Prices Increase 5.6% as Government Ramps Up Pressure to Lower Costs
▼ + stars: | 2023-02-02 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

Pharmaceutical companies raised list prices of 983 arthritis, cancer and other prescription drugs by an average of 5.6% at the start of this year—restrained increases as the industry faces a new federal law aimed at lowering medicine costs. Pfizer Inc., Novartis AG and Eli Lilly & Co. are among the companies that took the price increases through Jan. 31, according to 46brooklyn Research, a nonprofit drug-pricing analytics group. In recent days, Germany’s Merck KGaA raised the list prices of 11 products, including the multiple-sclerosis therapy Rebif.

☆ Drugmakers Raise Prices on Nearly 1,000 Medicines but Show Restraint
▼ + stars: | 2023-02-02 | by ( Jared S. Hopkins | ) www.wsj.com time to read: 1 min

☆ How to help loved ones with disabilities during the holidays, from a TV host whose family struggled with aunt's MS diagnosis
▼ + stars: | 2022-12-20 | by ( Renée Onque | ) www.cnbc.com time to read: +3 min

Jeannie Mai Jenkins, a TV host on syndicated talk show "The Real," kept her Aunt Linh's multiple sclerosis (MS) diagnosis a secret from her other family members, until her aunt was ready to tell them herself. Once her family became aware of her aunt's condition, they decided to change how they approached the holidays. Those taxing gatherings also influenced Mai Jenkins to get involved with Express4MS, a new campaign that aims to provide visibility into the journeys of people living with the disease. Ultimately, her family made adjustments that could help people with conditions beyond MS, too. "If you have someone in your family who has a condition of any kind, keep this in mind," she adds.

☆ French drug agency says under investigation over thyroid drug
▼ + stars: | 2022-12-06 | by ( ) www.reuters.com time to read: +1 min

[1/2] The logo of German pharmaceuticals company Merck is seen in front of the company's headquarters in Darmstadt, Germany, May 16, 2016. REUTERS/Kai Pfaffenbach/File PhotoCompanies Merck KGaA FollowPARIS, Dec 6 (Reuters) - France's ANSM national drug agency said it is under formal investigation on suspicion of issuing misleading information regarding German drugmaker Merck's (MRCG.DE) thyroid drug Levothyrox, adding it contested the provisional charges. The French Association of Thyroid Patients on Tuesday welcomed the development, but expressed disappointment that the provisional charges had not been more far-reaching. A court in the French city of Marseille had in October already placed Merck under formal investigation, meaning it is treated as a formal suspect but the case may yet be dropped. Merck said in October the investigation against it did not concern in any way the new formula for Levothyrox, but the way it provided information when changing from the old one.

☆ It's 'early innings' in the fertility market. Here's how to play the booming business with under-the-radar names
▼ + stars: | 2022-11-17 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

The multibillion dollar global fertility market is ripe with opportunity. For investors thinking about the fertility market, pharma firms may come to mind. In fact, the number of employers looking at fertility benefits as a "must have" has skyrocketed, she said. The global market size for fertility within the private women's health market should reach $72 billion by 2027, a report by FemTech Focus and Coyote Ventures found. Just like there were a wave of fintech companies going public, she expects fertility companies to eventually follow suit.

☆ New U.S. cancer drug prices rise 53% in five years -report
▼ + stars: | 2022-11-02 | by ( Deena Beasley | ) www.reuters.com time to read: +4 min

"I do think there is a possibility we see launch prices go up," she said. Reuters GraphicsPorter, who championed inflation-based caps on drug prices, is calling for additional national legislation to link launch prices to how well a drug works. The report found that the average launch price of a self-administered cancer drug, after adjusting for inflation, rose by nearly 26% to $238,000 between 2017 and 2021. By 2022, six out of the eight newly-launched oral cancer drugs had prices over $200,000 per year. Based on current trends, the report calculated that by 2026, when Medicare will first be able to negotiate drug prices, the average self-administered cancer drug launch price will be nearly $325,000 per year and over $525,000 for pills and biologics.

Meanwhile, Merck's investment strategy in China has not changed but the healthcare and chip materials maker is "mindful of the potential risks", Garijo noted in the Reuters Newsmaker interview. China is a key region for the semiconductor industry and drug companies, but geopolitical challenges are growing. While Taiwan has lived under the Chinese threat for decades, war games in early August have rattled nerves in the semiconductor industry. There is a need for "constructive dialogue" with markets like China that are important to German industry, and Merck, said Garijo. "We are mindful of the potential risks ... but our investment policy has not changed," she said.

☆ A potential gas shortages poses no major risk to our 2022 outlook, Merck KGaA CFO says
▼ + stars: | 2022-09-20 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailA potential gas shortages poses no major risk to our 2022 outlook, Merck KGaA CFO saysMarcus Kuhnert, CFO of science and technology company Merck KGaA, discusses the firm's third-quarter outlook and the implications of Europe's energy crisis on the business.

Search resuls for: "Merck KGaA"

21 mentions found